Venus Remedies touches roof on getting marketing approval from 4 countries for chemotherapy drugs
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Venus Remedies is currently trading at upper limit of Rs. 273.80, up by 13.00 points or 4.98 % from its previous closing of Rs. 260.80 on the BSE.
The scrip opened at Rs. 262.00 and has touched a high and low of Rs. 273.80 and Rs. 262.00 respectively. So far 18332 shares were traded on the counter.
The BSE group 'T' stock of face value Rs. 10 has touched a 52 week high of Rs. 273.80 on 6-Jul-2023 and a 52 week low of Rs. 145.00 on 08-Feb-2023.
Last one week high and low of the scrip stood at Rs. 273.80 and Rs. 238.25 respectively. The current market cap of the company is Rs. 365.99 crore.
The promoters holding in the company stood at 41.76%, while Institutions and Non-Institutions held 1.00% and 57.24% respectively.
Venus Remedies has received marketing approval from Oman, Malaysia, Bosnia and Trinidad and Tobago for key chemotherapy drugs. With this, it has secured 503 marketing approvals for its oncology products across 75 countries.
These marketing approvals will enable it to expand its operations to new geographies and open up new avenues for advanced cancer treatment with improved outcomes for patients battling various types of cancer.
Venus Remedies is one of the handful player in pharmaceutical sector to launch world global injectable manufacturers.
